Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Advanced Search
  • Jun 25, 2020
    - New data reinforce Abbott's leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies
    - Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott's innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings
  • May 21, 2020
    - Abbott's antibody test to be deployed as part of the UK Secretary of State for Health's initiative for highly-reliable, large-scale antibody testing
    - European-made blood test will run on Abbott's ARCHITECT® i1000SR and i2000SR, as well as its Alinity™ i laboratory instruments
    - 800,000 Abbott tests have already been delivered to NHS laboratories across the UK
    - Test demonstrated reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days or more after symptoms started
  • May 12, 2020
    - Alinity m is Abbott's new molecular lab system, which was approved by the U.S. FDA in March
    - The Alinity m system is highly advanced and greatly improves speed and efficiency, running up to 1,080 tests in 24 hours
    - Abbott is launching Alinity m to U.S. customers and will be making the SARS-CoV-2 test available for use under an Emergency Use Authorization
    - This is Abbott's fifth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic
  • May 11, 2020
    - Data shows reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days after symptoms began
    - Abbott plans to ship nearly 30 million antibody tests globally in May across its ARCHITECT and Alinity i platforms and will have capacity for 60 million in June
    - Abbott expects to submit for CE Mark for its Alinity i SARS-CoV-2 IgG test this week and will initiate global shipments immediately
    - This is Abbott's fourth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic
  • Apr 9, 2020
    - CE Mark for TriClip represents an important treatment option for people with severe tricuspid regurgitation, a difficult-to-manage heart condition
    - New system offers a proven safe and effective minimally invasive non-surgical solution
    - The TriClip System leverages Abbott's proven clip-based technology used in its MitraClip™ transcatheter mitral valve therapy
Show 5102550100 per page
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?